Poor
Not Aligned
Patient Risk:
High
Summary
Several dosage and program/cost claims are not supported by the provided CAMZYOS prescribing-information excerpts. Key dosing details conflict with the label (starting dose, maximum dose, and clinical-response basis). Indication-related claims are largely consistent with the excerpted indications (functional capacity/symptoms for symptomatic NYHA II–III obstructive HCM), but additional label elements (population/NHYA class specificity) are partially missing.
Category Scores
Accurate Statements
Camzyos is an oral medication taken by capsule.
The provided label excerpt states CAMZYOS is taken orally once daily and refers to oral dosing; it does not explicitly state capsule in the excerpt, but oral capsule is consistent with “orally once daily” and the product description.
Camzyos dosing is individualized and typically starts at 2 mg once daily.
Label supports dose titration/individualization based on clinical status with regular LVEF/LVOT assessments; however the specific “typically starts at 2 mg” is contradicted (see contradictions).
Dose adjustments for Camzyos are made based on a patient's clinical response, including left ventricular (LV) systolic function and symptom severity.
Label requires regular LVEF and Valsalva LVOT gradient assessment for careful titration and to avoid heart failure symptoms, prompting dose adjustment accordingly.
Unsupported Statements
The list price for Camzyos (mavacamten) is $60,000 per year.
No pricing information is present in the provided prescribing-information excerpts.
Camzyos costs approximately $5,000 per month for the medication itself (based on the list price).
No pricing information is present in the provided prescribing-information excerpts.
The MYCAMZYOS Program offers a co-pay card that could reduce out-of-pocket costs to as low as $10 per month for eligible patients.
No MYCAMZYOS program, co-pay card, or out-of-pocket cost figures are present in the provided prescribing-information excerpts.
The MYCAMZYOS Program does not apply to patients with government-funded insurance such as Medicare, Medicaid, or TRICARE.
No MYCAMZYOS program eligibility details regarding government insurance are present in the provided prescribing-information excerpts.
Bristol Myers Squibb Access Support Program can provide free medication for eligible uninsured or underinsured patients who meet certain financial criteria.
No access support program or free-medication program details are present in the provided prescribing-information excerpts.
Contradictions
High
AI Statement
Camzyos dosing is individualized and typically starts at 2 mg once daily.
Label Reference
SECTION 2.1: “The recommended starting dose is 5 mg orally once daily …”
High
AI Statement
The maximum recommended dose of Camzyos is 25 mg once daily.
Label Reference
SECTION 2.1: “The maximum recommended dose is 15 mg orally once daily.”
Moderate
AI Statement
Camzyos dosing is individualized and typically starts at 2 mg once daily.
Label Reference
SECTION 2.1: starting dose is 5 mg; 2.5 mg is mentioned as allowable titration and as an initiation dose when on certain interacting therapies (SECTION 2.2).
Important Omissions
Indication is for adults with symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM), but the claims state only “adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM)” (NYHA II–III not specified).
Importance:
Moderate
No mention of label-required LVEF initiation restriction (initiation/up-titration not recommended with LVEF <55%) and the interruption requirement for LVEF <50% (material dosing/safety requirements).
Importance:
High
No mention that titration requires LVEF and Valsalva LVOT gradient assessment and ongoing monitoring (material monitoring requirement).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Contradictory dosing statements (incorrect typical starting dose and incorrect maximum recommended dose) combined with omission of key label initiation/interruption LVEF thresholds and required monitoring could mislead safe prescribing/titration based on the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple label-inconsistent dosing claims (starting dose and maximum dose) and absence of required label monitoring/LVEF stopping criteria; plus unsupported non-label claims about pricing and patient assistance programs.
Suggested Improvement
Replace dosing claims with label-accurate starting dose (5 mg orally once daily) and maximum recommended dose (15 mg orally once daily), specify that 2.5 mg initiation is only in certain interacting-therapy scenarios (SECTION 2.2), and include the label’s LVEF initiation restriction (not recommended with LVEF <55%), treatment interruption if LVEF <50%, and required LVEF/Valsalva LVOT monitoring. Remove or qualify all pricing/program/co-pay claims unless supported by the provided label text.